Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
27,591,708
-
Shares change
-
+9,691,942
-
Total reported value, excl. options
-
$50,216,835
-
Value change
-
+$17,655,350
-
Put/Call ratio
-
130%
-
Number of buys
-
19
-
Number of sells
-
17
-
Price
-
$1.82
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q2 2024
As of 30 Jun 2024 Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) had 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 27,591,708 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, SAMLYN CAPITAL, LLC, Point72 Asset Management, L.P., ADAMS STREET PARTNERS LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, TOWERVIEW LLC, and MORGAN STANLEY.
This table shows 46 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.